Developer docs
API playgroundTry for free, no card

Search company profiles

Oculogica

Full company profile

uuid0000hc6

Namestring
Oculogica
Legal namestring
Oculogica, Inc.
Websiteurl
oculogica.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Oculogica is a privately-held neuro-diagnostics company founded in 2013 that develops and commercializes FDA-cleared, eye-tracking-based concussion assessment devices. The company sells two products: EyeBOX, an in-clinic device that captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements via infrared tracking to produce a BOX Score and 14 additional metrics in under four minutes without requiring a pre-injury baseline; and SNAP, a portable, battery-powered 90-second multimodal assessment that combines eye-tracking metrics with patient-reported symptom severity to produce a SNAP Score with 90% sensitivity and 94% specificity. Both products target clinical decision-making for concussion and mild traumatic brain injury in settings ranging from sports medicine clinics and pediatric urgent care to military/veteran facilities and personal injury/IME workflows.

Oculogica generates revenue primarily through capital equipment sales of EyeBOX and SNAP to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions, supplemented by training and support services. Pricing is not publicly disclosed; the company uses a consultative, quote-based sales motion initiated through a "Request a Demo" web form. Distribution combines direct enterprise field sales (e.g., Mayo Clinic, Rush University), an inside sales motion for mid-market clinics, and channel partners — notably XcelABLE, which embeds EyeBOX into Functional Capacity Evaluations and Independent Medical Examinations across all 50 U.S. states and globally, and the TRANSCENDENT Concussion Research Program in Ontario, Canada, which serves as the company's first (and currently only) Canadian site. The company holds six FDA clearances for concussion diagnostics — the most of any company in the industry — including the first FDA De Novo authorization for a baseline-free concussion test (December 2018) and the broadest label expansion in the industry (April 2025, ages 5-67, any time since injury, any injury type).

Operationally, Oculogica is a lean organization (1-10 employees) led by CEO Dr. Rosina Samadani, with founder Dr. Uzma Samadani serving as Scientific Advisor. The company is incorporated in Delaware with principal operations in New Richmond, Wisconsin. It has raised approximately $11M+ in disclosed funding from accredited investors, angel groups (Golden Seeds, Nebraska Angel Network, Southeast Minnesota Capital Fund, Sofia Fund), venture capital (TitletownTech, Colle Capital Partners), and U.S. government sources (Department of Defense, U.S. Army Medical Research & Development Command), with a $17.95M SEC exempt securities offering filed in May 2024. Technology credibility is supported by 16 peer-reviewed publications spanning 2014-2025 across journals including Military Medicine, Neurology, Journal of Neurotrauma, and Journal of Neurosurgery.

Short descriptiontext

Oculogica develops FDA-cleared, eye-tracking-based concussion diagnostic devices (EyeBOX and SNAP) that detect cranial-nerve-mediated eye movement disruption to deliver objective, baseline-free concussion assessment in under four minutes or 90 seconds for sports medicine, pediatric, military, urgent care, and personal injury/IME clinical settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
concussion diagnostics, eye tracking technology, neurodiagnostic devices, traumatic brain injury, medical device manufacturing
Industry2 codes
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Concussion Diagnostic Devices
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (EyeBOX and SNAP)
TypeHardware Sales
Description

Oculogica sells its FDA-cleared concussion diagnostic devices — EyeBOX (in-clinic, 4-minute assessment) and SNAP (portable sideline assessment) — to healthcare providers. Device sales to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions represent the primary revenue stream. Pricing is quote-based; no public pricing is listed.

oculogica.com
2Training and Support Services
TypeProfessional Services
Description

Oculogica provides device training and support to EyeBOX customers, including live training scheduling, training video libraries, and report interpretation guidance. Training videos are accessible to EyeBOX customers only, suggesting training/support may be bundled or offered as an ancillary service tied to device adoption.

oculogica.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Quote-based device pricing for EyeBOX and SNAP
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Sales are conducted through a 'Request a Demo' form, with pricing discussed during or following demonstrations. Device likely sold as a capital purchase or possibly as a subscription/service model for the software component.

oculogica.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1EyeBOX
Description

FDA-cleared concussion diagnostic device that uses proprietary eye-tracking technology to measure abnormal eye movements caused by concussion. Provides objective data independent of patient-reported symptoms. Delivers results in under 4 minutes without requiring a pre-injury baseline. Cleared for ages 5 to 67.

oculogica.com
+1 more record
Core offering1 text field

Oculogica develops and sells FDA-cleared concussion diagnostic medical devices built on proprietary eye-tracking technology. Its two commercial products are EyeBOX®, an in-clinic device that delivers an objective concussion assessment in under 4 minutes by analyzing 100,000 data points of cranial nerve-mediated eye movements, and SNAP™, a portable 90-second multimodal test combining eye-tracking with symptom severity for sideline and clinic use. Both products generate objective concussion scores without requiring pre-injury baselines and are cleared for ages 5-67 across any injury type and any time since injury.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SNAP achieved 90% sensitivity and 94% specificity in FDA 510(k) validation studies — the highest accuracy of any concussion test cleared by the FDA
+4 more records
Product overview1 text field

Oculogica offers two FDA-cleared concussion diagnostic products built on proprietary eye-tracking technology: EyeBOX and SNAP. EyeBOX is an in-clinic device providing objective concussion assessment in under 4 minutes without requiring a pre-injury baseline, cleared for ages 5-67. SNAP is a portable, 90-second concussion screening tool designed for sideline and clinical use, combining eye-tracking metrics with symptom input for rapid multimodal assessment. Both products use the same underlying eye-tracking science to detect concussion-related disruptions in cranial nerve function. The company has received six total FDA clearances for concussion diagnostics, the most of any company in the industry.

Product and service2 records
1EyeBOX® Concussion Diagnostic
CategoryConcussion Diagnostic Devices
Description

FDA-cleared in-clinic concussion diagnostic device using proprietary eye-tracking technology. Captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements during a non-invasive 4-minute assessment while the patient watches a video stimulus. Generates an objective BOX Score and 14 additional metrics compared against an age- and gender-normalized population. No pre-injury baseline, symptom input, language, or literacy required. Cleared for ages 5 to 67, any time since injury, any injury type. Targets hospitals, sports medicine clinics, urgent care, VA/military, personal injury clinics, and concussion research institutions.

2SNAP™ Concussion Test®
CategoryConcussion Diagnostic Devices
Description

FDA-cleared 90-second multimodal concussion test combining infrared eye tracking with patient-reported symptom severity to produce a composite SNAP Score. Portable, battery-powered, rugged form factor that works indoors and outdoors without requiring a pre-injury baseline. Achieves 90% sensitivity and 94% specificity. Designed for athletic trainers and urgent care clinicians for sideline screening and clinic use with adolescents and young adults.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-06-17
Description

XcelABLE, a global provider of Functional Capacity Evaluations (FCEs) and Independent Medical Examinations (IMEs), has partnered with Oculogica to include EyeBOX concussion diagnostics in all XcelABLE evaluations across all 50 U.S. states and globally. The partnership covers XcelABLE's credentialed clinician network and supports ongoing multi-university studies on biopsychosocial factors influencing concussion recovery. EyeBOX is integrated as an integral component of XcelABLE's FCE and IME offerings, providing objective data on concussion and TBI status to employers, insurers, and attorneys.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

The Ontario Brain Institute funds and supports the TRANSCENDENT Concussion Research Program, a research collaboration that is the first and only site in Canada to offer EyeBOX. OBI's provincial funding enables research-to-clinical deployment of Oculogica's technology, establishing EyeBOX as Health Canada registered diagnostic equipment in Canadian concussion care pathways.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

CHEO Research Institute leads the TRANSCENDENT Concussion Research Program in Canada. Dr. Roger Zemek serves as Senior Scientist at CHEO Research Institute and leads research teams in Ottawa and Toronto. CHEO's research endorsement and clinical infrastructure enable EyeBOX's Canadian adoption and clinical validation. CHEO is affiliated with the University of Ottawa.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-29
Description

360 Concussion Care is a multi-specialty concussion clinic (Ottawa, Toronto, Mississauga) that is part of the TRANSCENDENT Concussion Research Program. As a clinic network, it offers EyeBOX as part of its concussion care services and ongoing research, serving as a clinical distribution channel for Oculogica's technology in Canada.

Peers10 records
TypeDirect peer
Description

SyncThink develops eye-tracking-based concussion diagnostic technology (Eyesync) used in clinical and sports settings. It is the most direct head-to-head competitor to Oculogica's EyeBOX in the eye-tracking concussion diagnostic category, with comparable clinical positioning and FDA-cleared products.

TypeDirect peer
Description

BrainScope manufactures FDA-cleared EEG-based devices (BrainScope Ahead) for objective concussion and mild TBI assessment. It is a direct peer to Oculogica as an objective, FDA-cleared concussion diagnostic serving emergency departments, urgent care, and military customers.

TypeBroad incumbent
Description

ImPACT Applications is the established leader in computer-based neurocognitive concussion testing (ImPACT, ImPACT Pediatric), with broad adoption across sports leagues and clinical practices. It is a broad incumbent competing for the same clinical decision points that Oculogica targets, but with a fundamentally different (subjective) testing modality.

TypeDirect peer
Description

RightEye builds FDA-cleared eye-tracking diagnostic systems used to assess brain and vision health, including concussion and TBI applications. It overlaps directly with Oculogica's eye-tracking approach to concussion assessment while also addressing broader functional vision and neurological screening.

TypeEmerging player
Description

Quadrant Biosciences develops saliva-based biomarker concussion diagnostics (e.g., the Clarifi MDx test). It is an emerging player addressing the same concussion diagnostic use case as Oculogica but with a fundamentally different biological sample modality.

TypeEmerging player
Description

Sway Medical provides FDA-cleared balance and motion-based concussion assessment tools used by athletic trainers and clinicians. It addresses the same sideline and clinical concussion triage workflows that Oculogica's SNAP targets, using a complementary biomechanical modality.

TypeEmerging player
Description

HeadCheck Health offers a concussion assessment and management platform combining symptom evaluation with clinical decision support for sports medicine. It overlaps with Oculogica in the sideline concussion assessment workflow but is software-led rather than hardware-device-led.

TypeEmerging player
Description

C3 Logix develops multimodal concussion assessment tools incorporating neurocognitive, balance, and eye-tracking components. It overlaps with Oculogica in the clinical and sports medicine concussion assessment market, particularly with eye-tracking feature overlap.

9X2 Biosystems
TypeEmerging player
Description

X2 Biosystems produces wearable sensor-based concussion assessment tools (X-Patch) used in contact sports. It is an emerging player competing in the same sideline and clinical concussion evaluation workflows as Oculogica's SNAP.

TypeEmerging player
Description

NeuroSync (acquired by SyncThink) develops VR-based eye-tracking assessment technology for concussion. It represents an emerging modality competing in the same objective concussion diagnostic space that Oculogica's eye-tracking products serve.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oculogica

Concussion Diagnostic Devicesoculogica.com

Oculogica develops FDA-cleared, eye-tracking-based concussion diagnostic devices (EyeBOX and SNAP) that detect cranial-nerve-mediated eye movement disruption to deliver objective, baseline-free concussion assessment in under four minutes or 90 seconds for sports medicine, pediatric, military, urgent care, and personal injury/IME clinical settings.

What Oculogica does

Oculogica is a privately-held neuro-diagnostics company founded in 2013 that develops and commercializes FDA-cleared, eye-tracking-based concussion assessment devices. The company sells two products: EyeBOX, an in-clinic device that captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements via infrared tracking to produce a BOX Score and 14 additional metrics in under four minutes without requiring a pre-injury baseline; and SNAP, a portable, battery-powered 90-second multimodal assessment that combines eye-tracking metrics with patient-reported symptom severity to produce a SNAP Score with 90% sensitivity and 94% specificity. Both products target clinical decision-making for concussion and mild traumatic brain injury in settings ranging from sports medicine clinics and pediatric urgent care to military/veteran facilities and personal injury/IME workflows.

Oculogica generates revenue primarily through capital equipment sales of EyeBOX and SNAP to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions, supplemented by training and support services. Pricing is not publicly disclosed; the company uses a consultative, quote-based sales motion initiated through a "Request a Demo" web form. Distribution combines direct enterprise field sales (e.g., Mayo Clinic, Rush University), an inside sales motion for mid-market clinics, and channel partners — notably XcelABLE, which embeds EyeBOX into Functional Capacity Evaluations and Independent Medical Examinations across all 50 U.S. states and globally, and the TRANSCENDENT Concussion Research Program in Ontario, Canada, which serves as the company's first (and currently only) Canadian site. The company holds six FDA clearances for concussion diagnostics — the most of any company in the industry — including the first FDA De Novo authorization for a baseline-free concussion test (December 2018) and the broadest label expansion in the industry (April 2025, ages 5-67, any time since injury, any injury type).

Operationally, Oculogica is a lean organization (1-10 employees) led by CEO Dr. Rosina Samadani, with founder Dr. Uzma Samadani serving as Scientific Advisor. The company is incorporated in Delaware with principal operations in New Richmond, Wisconsin. It has raised approximately $11M+ in disclosed funding from accredited investors, angel groups (Golden Seeds, Nebraska Angel Network, Southeast Minnesota Capital Fund, Sofia Fund), venture capital (TitletownTech, Colle Capital Partners), and U.S. government sources (Department of Defense, U.S. Army Medical Research & Development Command), with a $17.95M SEC exempt securities offering filed in May 2024. Technology credibility is supported by 16 peer-reviewed publications spanning 2014-2025 across journals including Military Medicine, Neurology, Journal of Neurotrauma, and Journal of Neurosurgery.

Oculogica firmographics

Firmographics
Name
Oculogica
Legal name
Oculogica, Inc.
Website
https://oculogica.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Oculogica develops FDA-cleared, eye-tracking-based concussion diagnostic devices (EyeBOX and SNAP) that detect cranial-nerve-mediated eye movement disruption to deliver objective, baseline-free concussion assessment in under four minutes or 90 seconds for sports medicine, pediatric, military, urgent care, and personal injury/IME clinical settings.
Ownership category
akta.pro rank

Oculogica industry classification

Industry
Product category
Concussion Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Concussion diagnostics
  • Eye tracking technology
  • Neurodiagnostic devices
  • Traumatic brain injury
  • Medical device manufacturing

Where Oculogica is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Oculogica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Medical Device Sales (EyeBOX and SNAP): Oculogica sells its FDA-cleared concussion diagnostic devices — EyeBOX (in-clinic, 4-minute assessment) and SNAP (portable sideline assessment) — to healthcare providers. Device sales to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions represent the primary revenue stream. Pricing is quote-based; no public pricing is listed.
  2. Training and Support Services: Oculogica provides device training and support to EyeBOX customers, including live training scheduling, training video libraries, and report interpretation guidance. Training videos are accessible to EyeBOX customers only, suggesting training/support may be bundled or offered as an ancillary service tied to device adoption.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based device pricing for EyeBOX and SNAP

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Oculogica product offering

Product offering

Core offering

Oculogica develops and sells FDA-cleared concussion diagnostic medical devices built on proprietary eye-tracking technology. Its two commercial products are EyeBOX®, an in-clinic device that delivers an objective concussion assessment in under 4 minutes by analyzing 100,000 data points of cranial nerve-mediated eye movements, and SNAP™, a portable 90-second multimodal test combining eye-tracking with symptom severity for sideline and clinic use. Both products generate objective concussion scores without requiring pre-injury baselines and are cleared for ages 5-67 across any injury type and any time since injury.

Product overview

Oculogica offers two FDA-cleared concussion diagnostic products built on proprietary eye-tracking technology: EyeBOX and SNAP. EyeBOX is an in-clinic device providing objective concussion assessment in under 4 minutes without requiring a pre-injury baseline, cleared for ages 5-67. SNAP is a portable, 90-second concussion screening tool designed for sideline and clinical use, combining eye-tracking metrics with symptom input for rapid multimodal assessment. Both products use the same underlying eye-tracking science to detect concussion-related disruptions in cranial nerve function. The company has received six total FDA clearances for concussion diagnostics, the most of any company in the industry.

Differentiator

Problem solved

Functional benefit

Brands

  • EyeBOX: FDA-cleared concussion diagnostic device that uses proprietary eye-tracking technology to measure abnormal eye movements caused by concussion. Provides objective data independent of patient-reported symptoms. Delivers results in under 4 minutes without requiring a pre-injury baseline. Cleared for ages 5 to 67.
  • SNAP

Products and services

  • EyeBOX® Concussion Diagnostic FDA-cleared in-clinic concussion diagnostic device using proprietary eye-tracking technology. Captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements during a non-invasive 4-minute assessment while the patient watches a video stimulus. Generates an objective BOX Score and 14 additional metrics compared against an age- and gender-normalized population. No pre-injury baseline, symptom input, language, or literacy required. Cleared for ages 5 to 67, any time since injury, any injury type. Targets hospitals, sports medicine clinics, urgent care, VA/military, personal injury clinics, and concussion research institutions.
  • SNAP™ Concussion Test® FDA-cleared 90-second multimodal concussion test combining infrared eye tracking with patient-reported symptom severity to produce a composite SNAP Score. Portable, battery-powered, rugged form factor that works indoors and outdoors without requiring a pre-injury baseline. Achieves 90% sensitivity and 94% specificity. Designed for athletic trainers and urgent care clinicians for sideline screening and clinic use with adolescents and young adults.

Quantifiable outcome

  • SNAP achieved 90% sensitivity and 94% specificity in FDA 510(k) validation studies — the highest accuracy of any concussion test cleared by the FDA
  • +4 more outcomes

Companies that use Oculogica

Customer profile

Named customers8 records

Segments7 records

Ideal customer profiles5 records

Oculogica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Oculogica partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • XcelABLEcoreImplementation/ SI/ Consulting Partner · 17 June 2025XcelABLE, a global provider of Functional Capacity Evaluations (FCEs) and Independent Medical Examinations (IMEs), has partnered with Oculogica to include EyeBOX concussion diagnostics in all XcelABLE evaluations across all 50 U.S. states and globally. The partnership covers XcelABLE's credentialed clinician network and supports ongoing multi-university studies on biopsychosocial factors influencing concussion recovery. EyeBOX is integrated as an integral component of XcelABLE's FCE and IME offerings, providing objective data on concussion and TBI status to employers, insurers, and attorneys.
  • Ontario Brain Institute (OBI)coreStrategic or Co-development Partner · 29 May 2025The Ontario Brain Institute funds and supports the TRANSCENDENT Concussion Research Program, a research collaboration that is the first and only site in Canada to offer EyeBOX. OBI's provincial funding enables research-to-clinical deployment of Oculogica's technology, establishing EyeBOX as Health Canada registered diagnostic equipment in Canadian concussion care pathways.
  • CHEO (Children's Hospital of Eastern Ontario) Research InstitutecoreStrategic or Co-development Partner · 29 May 2025CHEO Research Institute leads the TRANSCENDENT Concussion Research Program in Canada. Dr. Roger Zemek serves as Senior Scientist at CHEO Research Institute and leads research teams in Ottawa and Toronto. CHEO's research endorsement and clinical infrastructure enable EyeBOX's Canadian adoption and clinical validation. CHEO is affiliated with the University of Ottawa.
  • 360 Concussion CarecoreChannel Partner/ Reseller/ Distributor · 29 May 2025360 Concussion Care is a multi-specialty concussion clinic (Ottawa, Toronto, Mississauga) that is part of the TRANSCENDENT Concussion Research Program. As a clinic network, it offers EyeBOX as part of its concussion care services and ongoing research, serving as a clinical distribution channel for Oculogica's technology in Canada.

Scale indicators5 records

Oculogica competitors and assessment

Company assessment

Direct peers

  • SyncThink: SyncThink develops eye-tracking-based concussion diagnostic technology (Eyesync) used in clinical and sports settings. It is the most direct head-to-head competitor to Oculogica's EyeBOX in the eye-tracking concussion diagnostic category, with comparable clinical positioning and FDA-cleared products.
  • BrainScope: BrainScope manufactures FDA-cleared EEG-based devices (BrainScope Ahead) for objective concussion and mild TBI assessment. It is a direct peer to Oculogica as an objective, FDA-cleared concussion diagnostic serving emergency departments, urgent care, and military customers.
  • RightEye: RightEye builds FDA-cleared eye-tracking diagnostic systems used to assess brain and vision health, including concussion and TBI applications. It overlaps directly with Oculogica's eye-tracking approach to concussion assessment while also addressing broader functional vision and neurological screening.

Broad incumbents

  • ImPACT Applications: ImPACT Applications is the established leader in computer-based neurocognitive concussion testing (ImPACT, ImPACT Pediatric), with broad adoption across sports leagues and clinical practices. It is a broad incumbent competing for the same clinical decision points that Oculogica targets, but with a fundamentally different (subjective) testing modality.

Emerging players

  • Quadrant Biosciences: Quadrant Biosciences develops saliva-based biomarker concussion diagnostics (e.g., the Clarifi MDx test). It is an emerging player addressing the same concussion diagnostic use case as Oculogica but with a fundamentally different biological sample modality.
  • Sway Medical: Sway Medical provides FDA-cleared balance and motion-based concussion assessment tools used by athletic trainers and clinicians. It addresses the same sideline and clinical concussion triage workflows that Oculogica's SNAP targets, using a complementary biomechanical modality.
  • HeadCheck Health: HeadCheck Health offers a concussion assessment and management platform combining symptom evaluation with clinical decision support for sports medicine. It overlaps with Oculogica in the sideline concussion assessment workflow but is software-led rather than hardware-device-led.
  • C3 Logix: C3 Logix develops multimodal concussion assessment tools incorporating neurocognitive, balance, and eye-tracking components. It overlaps with Oculogica in the clinical and sports medicine concussion assessment market, particularly with eye-tracking feature overlap.
  • X2 Biosystems: X2 Biosystems produces wearable sensor-based concussion assessment tools (X-Patch) used in contact sports. It is an emerging player competing in the same sideline and clinical concussion evaluation workflows as Oculogica's SNAP.
  • NeuroSync: NeuroSync (acquired by SyncThink) develops VR-based eye-tracking assessment technology for concussion. It represents an emerging modality competing in the same objective concussion diagnostic space that Oculogica's eye-tracking products serve.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

Oculogica social profiles

Digital presence

Oculogica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oculogica leadership team

Management profile

Number of profiles

Profiles6 records

Oculogica funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oculogica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oculogica

What does Oculogica do?

Oculogica develops and sells FDA-cleared concussion diagnostic medical devices built on proprietary eye-tracking technology. Its two commercial products are EyeBOX®, an in-clinic device that delivers an objective concussion assessment in under 4 minutes by analyzing 100,000 data points of cranial nerve-mediated eye movements, and SNAP™, a portable 90-second multimodal test combining eye-tracking with symptom severity for sideline and clinic use. Both products generate objective concussion scores without requiring pre-injury baselines and are cleared for ages 5-67 across any injury type and any time since injury.

Is Oculogica a public or private company?

Oculogica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oculogica founded?

Oculogica was founded in 2013. It employs 11 to 50 people.

Where is Oculogica based?

Oculogica is headquartered in New York, United States, in the North America region.

How does Oculogica make money?

Two revenue lines are on record. Medical Device Sales (EyeBOX and SNAP) is the primary driver. The others are training and Support Services.

Who are Oculogica's main competitors?

Direct peers on record are SyncThink, BrainScope and RightEye. ImPACT Applications is listed as a broad incumbent. Emerging players are Quadrant Biosciences, Sway Medical, HeadCheck Health, C3 Logix, X2 Biosystems and NeuroSync.

Does Oculogica have an API?

No public API is recorded for Oculogica.

What industry is Oculogica in?

Oculogica's product category is Concussion Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesThe 90-Second Eye-Tracking Test That Can End Guesswork On The SidelineOculogica received FDA clearance on June 5, 2026, for SNAP, a portable eye-tracking device designed to objectively diagnose concussions in approximately 90 seconds. The device measures involuntary oculomotor metrics to bypass subjective symptom reporting, distinguishing itself from competitors by being baseline-free and suitable for sideline use.MassDeviceOculogica wins FDA clearance for 90-second concussion testOculogica, a New Richmond, Washington-based developer of non-invasive testing technology, announced it received FDA 510(k) clearance for its SNAP concussion test, a 90-second diagnostic that combines eye tracking with symptom severity. The test achieved 90% sensitivity and 94% specificity, which the company states is the highest accuracy of any concussion test cleared by the FDA. The SNAP test was developed over four years with funding from the U.S. Department of Defense and works both indoors and outdoors without requiring a pre-injury baseline.openPR.comMarket Structure, Key Trends, and Leading Company Analysis of Non-Invasive Brain Trauma Monitoring DevicesThe non-invasive brain trauma monitoring devices market is projected to reach $16.71 billion by 2030, growing at a compound annual growth rate of 11.7%, driven by increasing demand for remote neurological monitoring, AI-assisted neurodiagnostics, and improvements in emergency care infrastructure. In June 2025, XcelABLE partnered with Oculogica Inc. to integrate the EyeBOX concussion diagnostic device into clinical evaluation procedures, aiming to improve concussion assessment accuracy and accessibility. Additionally, Canon Medical Systems introduced its Aquilion Serve SP CT scanner equipped with the INSTINX AI workflow automation system in the United States in May 2024 to enhance neurological imaging capabilities.Northwestern's McCormick School of EngineeringNorthwestern Magazine: Identifying ConcussionsOculogica, the developer of the EyeBOX concussion diagnostic tool, is seeking broader coverage from large health insurers beyond its current partner UnitedHealthcare to expand market adoption. The device, which received FDA approval in 2018, utilizes eye-tracking technology to diagnose concussions and has been validated by the company's founder through personal use.MarketplaceHow one female CEO landed angel investmentsOculogica, a medical device company founded by Dr. Uzma Samadani and led by CEO Rosina Samadani, secured angel investments from the Golden Seeds network to support its EyeBox concussion diagnosis technology. The investment relationship provided not only capital but also strategic guidance on the investment ecosystem and business milestones. This funding enables the company to further develop its eye-tracking technology for diagnosing concussions.SecSEC FORM DOculogica, Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b), with total offering amounts reaching approximately $17.95 million. The company has sold over $7.5 million in securities to 24 investors since the first sale on April 26, 2024. This regulatory filing discloses the company's active capital raising efforts within the biotechnology sector.ForbesSisters Get Concussion Diagnostic Funded, FDA Approved, And ReimbursedOculogica, founded by sisters Uzma and Rosina Samadani, developed EyeBOX, an eye-tracking device that diagnoses concussions. The company raised $8 million in venture capital and grants, secured four FDA clearances, and installed the device at Mayo Clinic. It now faces reimbursement hurdles, needing a CPT Category I code.SecSEC FORM DOculogica, Inc. filed a Form D notice of exempt offering of securities with the SEC, dated June 23, 2022, claiming Rule 506(b) exemption. The offering totaled $4,500,000, with $4,048,963 sold and $451,037 remaining, involving 20 investors. No sales commissions or finder's fees were disclosed.BioSpaceOculogica Announces Launch of New EyeBOX® DeviceOculogica announced the launch of its new EyeBOX device, a lightweight, battery-operated diagnostic tool for concussions that received FDA clearance earlier this year. The device utilizes a proprietary algorithm to provide objective diagnosis in under four minutes and is designed for use in both clinical and sports settings across various age groups.